ETFs and AUM reflect what Dividend Vision tracks — the issuer's full lineup may be larger.
ARK Invest is known for actively managed ETFs focused on disruptive innovation and emerging technologies across digital assets and innovation themes. The firm operates a lineup of 7 funds targeting growth-oriented investors, including popular tickers like ARKK (flagship innovation fund), ARKG (genomics), ARKW (web innovation), and ARKF (fintech), among others. ARK's funds are characterized by concentrated portfolios of high-conviction stock picks and a research-driven approach to identifying companies positioned to benefit from technological transformation.
See our curated list of related YouTube videos on ARKG.
ETFs and AUM reflect what Dividend Vision tracks — the issuer's full lineup may be larger.
State Street Global Advisors (SSGA) is one of the largest ETF providers globally, known for its flagship SPDR suite of exchange-traded products that serve both institutional and retail investors across a broad range of asset classes. Their 88-fund lineup spans diverse strategies including sector exposure (Select Sector SPDR), income generation (Income and Select Sector SPDR Premium Income families), commodities (including the widely-held GLD gold ETF), bonds, ESG-focused investments, and thematic allocations, with popular tickers like DIA (Diamonds Trust), FEZ (Eurozone exposure), and JNK (high-yield bonds) among their most recognized funds. The issuer is characterized by its comprehensive coverage across multiple market segments and its emphasis on both traditional index-based products and specialized strategies like covered call income funds and factor-based investing.
See our curated list of related YouTube videos on XBI.
Projections assume the current yield and share price remain constant. Actual results will vary.
Total returns
ARKG has lagged XBI over the trailing twelve months, posting a 49.60% total return against 76.32%. The lead holds up over 10 years too: XBI has compounded at 10.04% a year, against 8.70% for ARKG. XBI has been the steadier holding, though — annualized volatility of 27.6% against 43.3% for ARKG. Figures are total returns: price change plus every distribution reinvested.
Total return with all distributions reinvested on the ex-dividend date, split-adjusted, as of July 23, 2026. YTD and 1Y are cumulative; longer windows are annualized. “Since Oct 2014” measures every fund from October 31, 2014 — the youngest fund's first trading day — so all funds share one comparison window. Volatility is the annualized standard deviation of daily total returns over the trailing 3 years. Sharpe and Sortino divide the annualized return in excess of the risk-free rate by, respectively, that volatility and the downside deviation (both over the trailing 3 years) — higher is better. Max drawdown is the largest peak-to-trough total-return decline over the same window — shallower is better.
Quick verdict
ARKG (ARK Genomic Revolution ETF) and XBI (SPDR S&P Biotech ETF) are both ETFs, but they take different approaches.
XBI currently shows a 0.07% distribution yield. ARKG has not yet established a full distribution history, so a comparable yield figure is not available.
XBI is cheaper with an expense ratio of 0.35% compared to 0.75%.
XBI is the larger fund by assets ($10.5B), which generally means tighter spreads and better liquidity.
Still deciding? Track ARKG & XBI for free
Create a free Dividend Vision account to keep them on a watchlist, get notified when they declare dividends, and see how much income they would add to your portfolio.
On a $10,000 investment, ARKG has no reported distribution yield yet, so a monthly income estimate is not available, while XBI would produce $0.58/month, at current distribution rates.
ARKG yield—
XBI yield0.07%
Cost & efficiency
Over 10 years on $10,000, ARKG would cost approximately $750 in fees vs $350 for XBI (simplified, not compounded). The $400.00 difference may be offset by yield or performance.
ARKG ER0.75%
XBI ER0.35%
Strategy & risk
ARKG is an ETF, while XBI tracks S&P Biotechnology Select Industry Index. Beta is 2.38 for ARKG and 1.1 for XBI, indicating XBI is less volatile relative to the market.
ARKG beta2.38
XBI beta1.1
Fund details
ARKG is managed by ARK Invest (launched 10/31/2014) with $1.62B in assets. XBI is managed by State Street (launched 01/31/2006) with $10.5B in assets.
Do us a favor — if you found this comparison useful, please share it with a friend researching dividend ETFs.
Frequently asked questions
Which of ARKG or XBI pays more dividend income?
XBI currently reports a distribution yield, while ARKG has not yet established a full distribution history. A direct income comparison is not yet meaningful — check back once both funds have published several consecutive distributions.
What is the difference between ARKG and XBI?
ARKG (ARK Genomic Revolution ETF) is an ETF, while XBI (SPDR S&P Biotech ETF) tracks S&P Biotechnology Select Industry Index. They are issued by ARK Invest and State Street respectively.
Can I hold both ARKG and XBI?
Yes — nothing prevents holding both. Whether the combination actually diversifies depends on how much the underlying exposures overlap, which isn't fully measurable from the data on this page; review each security's holdings, sector, and strategy before treating them as complementary.
Which has lower fees, ARKG or XBI?
ARKG has an expense ratio of 0.75% while XBI charges 0.35%. Lower fees mean more of your investment returns stay in your pocket over time.
How much income does $10,000 in ARKG vs XBI generate?
At current rates, ARKG has not established a distribution history yet, so a monthly income estimate is not available. The same in XBI would produce about $0.58 per month ($7.00 annually).
Which has performed better historically, ARKG or XBI?
ARKG has lagged XBI over the trailing twelve months, posting a 49.60% total return against 76.32%. The lead holds up over 10 years too: XBI has compounded at 10.04% a year, against 8.70% for ARKG. XBI has been the steadier holding, though — annualized volatility of 27.6% against 43.3% for ARKG. Figures are total returns: price change plus every distribution reinvested. Past performance does not guarantee future results.
Explore related screeners
Lateral filters that include these funds — browse the full peer set on DividendVision.
Still deciding? Compare them against your own portfolio
See how each ETF fits alongside your real holdings — forecast future income, analyze overlap, and gauge risk. Start a free 7-day Dividend Vision trial and make the call with your full portfolio in view.
